Hemp & CBD
•22 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (22)
%
| Company | Market Cap | Price |
|---|---|---|
|
Manitoba Harvest and hemp-based products place Tilray in Hemp & CBD.
|
$1.89B |
$1.72
-14.43%
|
|
Launch of hemp wrap offerings aligns with hemp-derived tobacco accessories category.
|
$1.75B |
$98.03
-0.53%
|
|
Hemp-derived CBD products are part of GTBIF's Farm Bill compliant offerings via Señorita and related brands.
|
$1.60B |
$7.27
-7.51%
|
|
CBD/hemp-derived product offerings as part of Cronos' portfolio (Lord Jones and related CBD products).
|
$1.01B |
$2.63
-0.75%
|
|
The U.S. CBD business (Balanced Health Botanicals / CBDistillery) indicates hemp-derived CBD product production and sales.
|
$371.84M |
$3.31
-9.81%
|
|
The company markets hemp/CBD-derived products (e.g., CBD lozenges) and CBD-related offerings, aligning with Hemp & CBD.
|
$290.85M |
$5.30
-12.11%
|
|
Ranco co-packing and hemp-based product manufacturing/license (Packwoods) directly implies hemp-derived CBD product production.
|
$238.57M |
$2.01
|
|
Engaged in hemp-derived CBD products and expanding into the U.S. hemp-derived beverage market.
|
$198.26M |
$1.91
-4.50%
|
|
Directly produces and sells hemp-derived THC beverages under the Señorita brand.
|
$91.73M |
$41.14
-2.02%
|
|
Includes hemp-derived/CBD products in its product portfolio, indicating a hemp/CBD revenue line.
|
$80.81M |
$0.40
-4.76%
|
|
Hemp-derived CBD products or non-flower cannabis product lines.
|
$72.92M |
$1.60
-4.76%
|
|
Company launched hemp-derived/alternative products (SPREE BAR), indicating inclusion of Hemp & CBD consumer goods.
|
$72.13M |
$0.32
-2.73%
|
|
Cannabinoid-based therapies derived from hemp/CBD fit Hemp & CBD products.
|
$33.48M |
$0.40
-4.29%
|
|
Pipeline includes CBD component (IHL-675A) in its formulation, CBD-based drug candidate.
|
$11.53M |
$0.39
-9.33%
|
|
cbdMD's core product lineup is hemp-derived CBD products (Hemp & CBD).
|
$10.96M |
$1.23
-13.99%
|
|
Direct hemp-derived CBD products under PlusCBD brand; core product category.
|
$7.37M |
$0.04
+1.15%
|
|
Pivot centers on premium skincare/wellness products with hemp/CBD elements, i.e., Hemp & CBD products.
|
$7.09M |
$0.06
-7.69%
|
|
Mary Jones HD9 is hemp-derived (Delta-9) beverage product, aligning with Hemp & CBD offerings.
|
$6.17M |
$0.16
-11.06%
|
|
BUDZ maintains an inventory of high THC strains and CBD/CBG strains via Hemp empirical Genetics, aligning with Hemp & CBD product categories.
|
$5.44M |
$0.04
-10.02%
|
|
Portfolio potentially includes hemp/CBD-related products within cannabis lifestyle and accessory offerings.
|
$5.27M |
$3.87
-4.91%
|
|
OWPC's pivot centers on hemp-derived CBD products (Pro-11) and hemp-based materials, directly aligning with Hemp & CBD product category.
|
$2.83M |
$0.02
-24.71%
|
|
Hemp-derived CBD products via the Gabriola Island facility (hemp license).
|
$905027 |
$2.18
-5.22%
|
Loading industry metrics...
Loading comparison data...
